RU2699285C2 - Одноцепочечные белки-агонисты trail-рецептора - Google Patents

Одноцепочечные белки-агонисты trail-рецептора Download PDF

Info

Publication number
RU2699285C2
RU2699285C2 RU2016145608A RU2016145608A RU2699285C2 RU 2699285 C2 RU2699285 C2 RU 2699285C2 RU 2016145608 A RU2016145608 A RU 2016145608A RU 2016145608 A RU2016145608 A RU 2016145608A RU 2699285 C2 RU2699285 C2 RU 2699285C2
Authority
RU
Russia
Prior art keywords
trail
seq
cell
receptor agonist
domain
Prior art date
Application number
RU2016145608A
Other languages
English (en)
Russian (ru)
Other versions
RU2016145608A (ru
RU2016145608A3 (enExample
Inventor
Оливер ХИЛЛ
Кристиан ГИФФЕРС
Майнольф Тиманн
Фриц Г. БЬЮКАНАН
Даррен К. ФИЛЛИПС
Сьюзан Э. ЛЭПП
Original Assignee
Эббви Инк.
Апогеникс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк., Апогеникс Аг filed Critical Эббви Инк.
Publication of RU2016145608A publication Critical patent/RU2016145608A/ru
Publication of RU2016145608A3 publication Critical patent/RU2016145608A3/ru
Application granted granted Critical
Publication of RU2699285C2 publication Critical patent/RU2699285C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
RU2016145608A 2014-04-23 2015-04-23 Одноцепочечные белки-агонисты trail-рецептора RU2699285C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983,152 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (3)

Publication Number Publication Date
RU2016145608A RU2016145608A (ru) 2018-05-28
RU2016145608A3 RU2016145608A3 (enExample) 2018-12-26
RU2699285C2 true RU2699285C2 (ru) 2019-09-04

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016145608A RU2699285C2 (ru) 2014-04-23 2015-04-23 Одноцепочечные белки-агонисты trail-рецептора

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3134430B1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN111718424A (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA2946402C (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA45069A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG11201608767XA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738831B2 (ja) * 2015-05-04 2020-08-12 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
JP6917368B2 (ja) 2015-10-23 2021-08-11 アポジェニックス アーゲー 一本鎖ｃｄ２７受容体アゴニストタンパク質
CA3002587A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
CN108473549A (zh) * 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 单链gitr受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
WO2017151707A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
CA3017622A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017283487A1 (en) * 2016-06-13 2018-11-22 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN111050784B (zh) * 2017-08-11 2024-03-19 伊利诺伊大学理事会 截短的豚鼠l-天冬酰胺酶变体及其使用方法
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
TW202002952A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
CN115836084A (zh) 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
EP4346885A1 (en) 2021-05-28 2024-04-10 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
SK288342B6 (en) 2000-12-07 2016-03-01 Lilly Co Eli GLP-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) * 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
EP1871798B1 (en) * 2005-04-15 2009-10-14 Rappaport Family Institute For Research in the Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2484691B1 (en) 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
MX2011002759A (es) 2008-09-22 2011-07-28 Amgen Inc Metodo de tratamiento.
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
WO2010085682A2 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
BR112012017164A2 (pt) * 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
AU2011240620A1 (en) 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
ES2674662T3 (es) * 2012-07-18 2018-07-03 Apogenix Ag Composición que comprende una mezcla de isoformas CD95-Fc

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUMMINS N. ET AL., The TRAIL to viral pathogenesis: the good, the bad and the ugly, Curr. Mol. Med., 2009, v.9, n.4, p.495-505. *
GIEFFERS C. ET AL., APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors, MOLECULAR CANCER THERAPEUTICS, 2013, v.12, n.12, p.2735-2747. *

Also Published As

Publication number Publication date
BR112016024515A2 (pt) 2017-10-10
PT3134430T (pt) 2018-04-20
AR100168A1 (es) 2016-09-14
TW202024123A (zh) 2020-07-01
CN106459221B (zh) 2020-09-01
WO2015164588A1 (en) 2015-10-29
US20150337027A1 (en) 2015-11-26
US9908927B2 (en) 2018-03-06
AU2020202247A1 (en) 2020-04-23
PH12016502079A1 (en) 2016-12-19
MY181986A (en) 2021-01-18
KR20170012257A (ko) 2017-02-02
CA2946402A1 (en) 2015-10-29
PH12016502079B1 (en) 2016-12-19
RU2016145608A (ru) 2018-05-28
NZ725476A (en) 2023-09-29
PH12020500377A1 (en) 2022-11-14
UA118286C2 (uk) 2018-12-26
MA45069A (fr) 2019-04-03
AU2015249649A1 (en) 2016-11-10
US20210040178A1 (en) 2021-02-11
EP3134430A1 (en) 2017-03-01
US20240174731A1 (en) 2024-05-30
JP6523331B2 (ja) 2019-05-29
RS57153B1 (sr) 2018-07-31
CA2946402C (en) 2023-02-28
EP3366699A1 (en) 2018-08-29
KR20190135546A (ko) 2019-12-06
LT3134430T (lt) 2018-05-10
IL272612A (en) 2020-03-31
HRP20180950T1 (hr) 2018-08-10
JP2019162114A (ja) 2019-09-26
ES2672368T3 (es) 2018-06-14
MX2016013858A (es) 2017-08-02
PE20170299A1 (es) 2017-05-06
RU2016145608A3 (enExample) 2018-12-26
TR201806912T4 (tr) 2018-06-21
PL3134430T3 (pl) 2018-08-31
AU2018271369A1 (en) 2018-12-20
CY1120281T1 (el) 2019-07-10
SI3134430T1 (en) 2018-05-31
SMT201800286T1 (it) 2018-07-17
KR102079919B1 (ko) 2020-02-24
JP2017513503A (ja) 2017-06-01
TWI747178B (zh) 2021-11-21
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
MX2019013587A (es) 2020-01-13
DK3134430T3 (en) 2018-05-22
SG10202111785VA (en) 2021-12-30
EP3134430B1 (en) 2018-03-21
SG10201806465TA (en) 2018-08-30
DOP2016000284A (es) 2017-02-15
UY36095A (es) 2015-10-30
CL2016002683A1 (es) 2017-07-07
SG11201608767XA (en) 2016-11-29
IL248244A0 (en) 2016-11-30
CR20160516A (es) 2017-05-10
ECSP16089579A (es) 2018-05-31
TW201620928A (zh) 2016-06-16
MA39770A (fr) 2015-10-29
BR112016024515B1 (pt) 2020-03-31
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
US20250145688A1 (en) 2025-05-08
JP6714751B2 (ja) 2020-06-24
NO2776305T3 (enExample) 2018-01-27
AU2015249649B2 (en) 2018-10-04
US20180222962A1 (en) 2018-08-09
HUE038914T2 (hu) 2018-12-28
IL248244B (en) 2020-03-31
TWI683825B (zh) 2020-02-01

Similar Documents

Publication Publication Date Title
RU2699285C2 (ru) Одноцепочечные белки-агонисты trail-рецептора
ES2754432T3 (es) Proteínas agonistas de receptor CD40 de cadena sencilla
AU2016341400A1 (en) Single-chain CD137-receptor agonist proteins
JP2018533948A (ja) 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
AU2016341402B2 (en) Single-chain GITR-receptor agonist proteins
US20180230196A1 (en) Single-chain ox40-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins